Menu Search
Equities

Cidara Therapeutics Inc

CDTX:NAQ

Cidara Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)20.58
  • Today's Change3.13 / 17.94%
  • Shares traded56.11k
  • 1 Year change+43.92%
  • Beta1.0453
Data delayed at least 15 minutes, as of Nov 22 2024 18:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 21-Nov-24
Select bar for recommendation details.
Recommendations21-Nov-24
Buy3
Outperform3
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 5 analysts offering 12 month price targets for Cidara Therapeutics Inc have a median target of 33.00, with a high estimate of 140.00 and a low estimate of 24.00. The median estimate represents a 89.11% increase from the last price of 17.45.
High702.3%140.00
Med89.1%33.00
Low37.5%24.00

Earnings history & estimates in USD

On Nov 07, 2024, Cidara Therapeutics Inc reported 3rd quarter 2024 losses of -2.45 per share. This result exceeded the -4.25 consensus loss of the 3 analysts covering the company and under-performed last year's 3rd quarter results by 36.11%.
The next earnings announcement is expected on Mar 24, 2025.
Average growth rate-204.61%
Cidara Therapeutics Inc reported annual 2023 losses of -5.20 per share on Apr 22, 2024.
Average growth rate+28.45%
More ▼

Revenue history & estimates in USD

Cidara Therapeutics, Inc. did not report revenues for the 3rd quarter 2024. However, during the 3rd quarter of the prior year the company reported revenues of 25.99m.
Average growth rate-52.51%
Cidara Therapeutics, Inc. had revenues for the full year 2023 of 63.91m. This was 0.60% below the prior year's results.
Average growth rate+74.40%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.